Parallel Advisors’s Inovio Pharmaceuticals INO Stock Holding History

Parallel Advisors’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-107	Closed	-$498	–	3392
2023 Q3	$498	Buy	+107	New	+$591	﹤0.01%	3105
2021 Q4	–	Sell	-16	Closed	-$1K	–	3179
2021 Q3	$1K	Buy	16 +2	+14%	+$201	﹤0.01%	2877
2021 Q2	$2K	Sell	14 -9	-39%	-$864	﹤0.01%	2574
2021 Q1	$3K	Buy	+23	New	+$3.02K	﹤0.01%	2373
2020 Q4	–	Sell	-25	Closed	-$3.33K	–	2630
2020 Q3	$3K	Buy	25 +21	+525%	+$4.38K	﹤0.01%	2189
2020 Q2	$1K	Sell	4 -6	-60%	-$963	﹤0.01%	2327
2020 Q1	$0	Buy	+10	New	+$617	﹤0.01%	2508
2019 Q1	–	Sell	-26	Closed	-$1K	–	2335
2018 Q4	$1K	Hold	26	–	–	﹤0.01%	2015
2018 Q3	$2K	Hold	26	–	–	﹤0.01%	2013
2018 Q2	$1K	Hold	26	–	–	﹤0.01%	1981
2018 Q1	$1K	Buy	+26	New	+$1.41K	﹤0.01%	1987
2017 Q3	–	Sell	-25	Closed	-$2K	–	2154
2017 Q2	$2K	Buy	+25	New	+$2.14K	﹤0.01%	1876

Other funds holding INO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

GCP

GSA Capital Partners London, United Kingdom $1.61B AUM 28.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Parallel Advisors's INO Position: Q4 2023 in Review

Parallel Advisors sold out of Inovio Pharmaceuticals (INO) in Q4 2023, closing a stake of 107 shares — an estimated $498 sold.

Parallel Advisors first reported a position in INO in Q2 2017 and held it in 12 quarters. The position peaked at $3K in Q1 2021. 113 funds tracked by Wall St. Rank hold INO as of Q4 2023.

Parallel Advisors reported no remaining Inovio Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
Parallel Advisors sold 107 Inovio Pharmaceuticals shares in Q4 2023, an estimated $498.
Parallel Advisors first reported a position in Inovio Pharmaceuticals in Q2 2017 and held it in 12 quarters.
Parallel Advisors's Inovio Pharmaceuticals position peaked at $3K in Q1 2021.
113 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q4 2023.

Based on Parallel Advisors's 13F filing for Q4 2023, filed 12 Feb 2024.